FDA approves Bay Area company's colon cancer screening test

The FDA has approved a new colon cancer screening method, the shield test, developed by Guardant Health, which simplifies screening to a blood test. This test aims to increase screening rates among those who avoid traditional methods like colonoscopies. It is particularly targeted at individuals aged 45 and older with an average risk of colon cancer, and research indicates it is 83% effective in detecting colorectal cancers. The approval is expected to enhance insurance coverage, making the test more accessible.

Keywords: colon cancer, FDA approval, blood test

Source: NBC Bay Area

Update At: 7/30/2024